Division of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura 281 406, India.
Division of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura 281 406, India.
Neuropeptides. 2021 Apr;86:102122. doi: 10.1016/j.npep.2021.102122. Epub 2021 Jan 9.
Renin Angiotensin System plays significant role in the memory acquisition and consolidation apart from its hemodynamic function in the pathophysiology of Alzheimer's disease (AD). It has been reported that Ang (1-7) ameliorates the cognitive impairment in experimental animals. However, the effect of Ang (1-7)/Mas receptor signaling is yet to be explored in Aβ42-induced memory impairment. Aβ42 was intracerebroventricularly injected into the male rats on day-1 (D-1) of the experimental schedule of 14 days. All the drugs were administered from D-1 to D-14 in the study design. Aβ42 significantly increased the escape latency during Morris water maze (MWM) test on D-10 to13 in the animals. Further, Aβ42 significantly decreased the time spent and percentage of total distance travelled in the target quadrant of the rats on D-14 in the MWM test. Aβ42 also significantly decreased the spontaneous alteration behavior on D-14 during Y-maze test. Moreover, there was a significant increase in the level of Aβ42, decrease in the cholinergic function (in terms of decreased acetylcholine and activity of cholinesterase, and increased activity of acetylcholinesterase), mitochondrial function, integrity and bioenergetics, and apoptosis in all the rat brain regions. Further, Aβ42 significantly decreased the level of expression of heme oxygenase-1 in all the rat brain regions. Ang (1-7) attenuated Aβ42-induced changes in the behavioral, biochemical and molecular observations in all the selected rat brain regions. However, A779, Mas receptor blocker, significantly abolished the beneficial effects of Ang (1-7) in Aβ42-induced cognitive deficit animals. These observations clearly indicate that the Ang (1-7)/Mas receptor activation could be a potential alternative option in the management of AD.
肾素血管紧张素系统在阿尔茨海默病(AD)的病理生理学中除了其血液动力学功能外,在记忆获得和巩固中也起着重要作用。据报道,血管紧张素(1-7)可改善实验动物的认知障碍。然而,血管紧张素(1-7)/Mas 受体信号在 Aβ42 诱导的记忆障碍中的作用尚未得到探索。在实验方案的第 14 天(D-1),将 Aβ42 脑室内注射到雄性大鼠中。在研究设计中,所有药物均于 D-1 至 D-14 给药。Aβ42 显著增加了动物在 Morris 水迷宫(MWM)测试中的逃避潜伏期,从 D-10 到 D-13。此外,Aβ42 显著降低了 MWM 测试中大鼠目标象限的停留时间和总距离百分比。Aβ42 还显著降低了 Y 迷宫测试中 D-14 期间的自发改变行为。此外,所有大鼠脑区的 Aβ42 水平显著升高,胆碱能功能(表现为乙酰胆碱和胆碱酯酶活性降低,乙酰胆碱酯酶活性升高)、线粒体功能、完整性和生物能量学以及细胞凋亡显著降低。此外,Aβ42 还显著降低了所有大鼠脑区血红素加氧酶-1 的表达水平。血管紧张素(1-7)减轻了 Aβ42 诱导的所有选定大鼠脑区行为、生化和分子观察的变化。然而,Mas 受体阻断剂 A779 显著消除了血管紧张素(1-7)在 Aβ42 诱导的认知缺陷动物中的有益作用。这些观察结果清楚地表明,血管紧张素(1-7)/Mas 受体激活可能是 AD 管理的一种潜在替代选择。